James Paul Scopa

James Paul Scopa (board member) discloses dealings in 6 companies, chiefly Peplin Inc, DICE Therapeutics, Inc. and Adverum Biotechnologies, Inc. We count 44 filings; the first trade dates from 13 January 2009 and the latest from 9 December 2025.

On the open market, the record shows 20 purchases worth €2.0M and 2 sales worth €369k. On balance, insiders were net buyers of €1.7M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 1 share grant and 1 option exercise.

In size, the median ticket on the buying side is €8,839. 1 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 10 December 2025 with a transaction in Adverum Biotechnologies, Inc. The most recent open-market purchase was published on 9 February 2024, 988 days ago. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.